AIM IP specialist Tekcapital to sell or float all four portfolio companies 'within 2 years'. Watch the full video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7,735.00
Bid: 7,728.00
Ask: 7,730.00
Change: 55.00 (0.72%)
Spread: 2.00 (0.03%)
Open: 7,682.00
High: 7,745.00
Low: 7,673.00
Yest. Close: 7,680.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

TOP NEWS: Positive Results For AstraZeneca Drugs Imfinzi And Lynparza

Fri, 18th Sep 2020 09:21

(Alliance News) - AstraZeneca PLC on Friday said updated results from its Pacific phase 3 trial of Imfinzi showed a sustained and clinically meaningful improvement in overall survival and progression-free survival in lung cancer.

The trial was of patients with unresectable, stage 3 non-small cell lung cancer who had not progressed after concurrent chemoradiation therapy. One in three patients with non-small cell lung cancer are diagnosed at stage 3, at which point most tumours are unresectable - meaning they cannot be removed with surgery.

Before Imfinzi in this setting, there have been no new treatments past chemoradiation therapy in decades.

Results from the updated post-hoc analyses showed an estimated four-year survival rate with Imfinzi of 50% compared to 36% with placebo after chemoradiation therapy. Median overall survival was 47.5 months for Imfinzi and 29.1 months with placebo.

At the maximum treatment course of one year, around 35% of patients treated with the drug had not progressed four years after enrolment compared to 20% with placebo.

Jose Baselga, executive vice president of Oncology R&D as Astra, said: "These unprecedented four-year results reinforce Imfinzi as the established standard of care in unresectable, stage 3 non-small cell lung cancer and set a new survival benchmark in a setting where cure is the treatment goal. With data also at ESMO for Caspian in small cell lung cancer patients, Imfinzi continues to deliver impressive long-term benefits across different types of lung cancer."

In the primary analysis of Pacific phase 3, the most comment adverse events among patients were cough, which 35% experienced compared to 25% with the placebo; fatigue, 24% versus 21%; dyspnoea, 22% versus 24%; and radiation pneumonitis, 20% versus 16% with placebo. A grade 3 or 4 adverse event occurred in 31% of patients treated with Imfinzi compared to 26% with placebo. A total of 15% of patients discontinued Imfinzi treatment due to adverse events compared to 9.8% with placebo.

Astra also posted results from the Caspian phase 3 trial exploratory subgroup analyses in extensive-stage small cell lung cancer. These subgroup analyses were conducted to characterise patients deriving long-term benefit.

Over three times as many patients treated with Imfinzi plus chemotherapy were alive and progression-free for a year or more versus chemo alone, 17% compared to 4.5%.

In all treatment arms, those patients who were progression free at 1 year had a 75% chance of being alive at 2 years. In comparison, those patients whose disease did progress within a year had a 10% change of being alive at 2 years.

Caspian met its primary endpoint of overall survival in 2019, reducing risk of death by 27% in extensive-stage small cell lung cancer.

Separately on Friday, Astra posted five-year data from its Solo-1 phase 3 trial of another cancer drug, Lynparza. This is the longest follow-up analysis for any PARP inhibitor in the first-line maintenance setting.

Data showed that Lynparza improved median time patients lived without disease progression to more than 4.5 years in BRCA-mutated advanced ovarian cancer, compared to just over 1 year with placebo.

BRCA mutations are associated with certain cancers, with around 22% of patients with ovarian cancer having a BRCA1/2 mutation.

PARP is an enzyme in cells that helps to repair damaged DNA, and so inhibiting this enzyme prevents cancer cells from repairing themselves.

The five-year follow-up showed that Lynparza reduced risk of disease progression or death by 67% to a median of 56.0 months compared to 13.8 months with placebo. At five years, 48% of patients treated with the drug remained free from disease progression compared to 21% with placebo. The median duration of Lynparza treatment was 24.6 months compared to 13.9 months with placebo.

Baselga said: "Once a patient's ovarian cancer recurs, it historically has been incurable. Even at an advanced stage, we have shown that maintenance treatment with Lynparza can help patients achieve sustained remission. Today's results further underline the critical importance of identifying a patient's biomarker status at the time of diagnosis to offer a treatment that may help delay disease progression."

Astra is developing Lynparza with Kenilworth, New Jersey-based drug maker Merck & Co Inc as part of a strategic oncology collaboration.

Shares in Astra were up 0.8% at 8,718.00 pence in London on Friday morning.

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News

UPDATE 1-AstraZeneca weighs seeking full U.S. approval for COVID shot - WSJ

(Adds background related to AstraZeneca vaccine)May 7 (Reuters) - AstraZeneca Plc may skip asking the U.S. Food and Drug Administration for emergency-use authorization for its COVID-19 vaccine and instead pursue the more time-intensive application...

Today 23:23

AstraZeneca weighs seeking full U.S. approval for COVID-19 shot -WSJ

May 7 (Reuters) - AstraZeneca Plc may skip asking the U.S. Food and Drug Administration for emergency-use authorization for its COVID-19 vaccine, and instead pursue the more time-intensive application for a full-fledged license to sell the shot, ...

Today 22:52

INSIGHT-How the U.S. locked up vaccine materials other nations urgently need

By Allison Martell and Euan RochaMay 7 (Reuters) - To fight the pandemic at home, the United States gave its own vaccine manufacturers priority access to American-made materials needed to make the shots.As a result, the U.S. government laid claim n...

Today 16:00

WRAPUP 1-Britain, Germany in role reversal on AstraZeneca vaccine risks

* Britain restricts AstraZeneca to people aged over 40* In Germany, all adults free to get AZ shot on doctor's advice* Germany, with eye on summer hols, shortens gap between doses* EU regulator looking at AZ on reports of neurological illnessBy Al...

Today 15:34

UPDATE 1-Vietnam reports first death in patient who received AstraZeneca COVID-19 vaccine

(Adds details and background)By Khanh VuHANOI, May 7 (Reuters) - Vietnam's health ministry on Friday reported its first death in a patient who received AstraZeneca's COVID-19 vaccine shot, as the country is battling a new outbreak.A 35-year-old fe...

Today 15:31

Vietnam reports first death in patient who received AstraZeneca COVID-19 vaccine

HANOI, May 7 (Reuters) - Vietnam's health ministry on Friday reported its first death in a patient who received AstraZeneca's COVID-19 vaccine shot.A 35-year-old female health worker in the southern province of An Giang died on Friday, one day aft...

Today 14:54

UPDATE 1-EU regulator reviews reports of rare nerve disorder after AstraZeneca shot

(Adds details from EMA statement on other vaccines, background)May 7 (Reuters) - Europe's medicines regulator said on Friday it was reviewing reports of a rare nerve-degenerating disorder in people who have received AstraZeneca's COVID-19 vaccine,...

Today 13:15

UPDATE 2-EU reviews reports of rare nerve disorder after AstraZeneca's COVID-19 shot

* EMA reviewing AstraZeneca vaccine for Guillain-Barre syndrome* Rare nerve syndrome also linked some vaccinations in past* EMA also assessing heart inflammation with Pfizer, Moderna shots* Studies into possible links to rare blood clots ongoing (...

Today 13:15

UPDATE 3-EU reviews reports of rare nerve disorder after AstraZeneca's COVID-19 shot

* EMA reviews AstraZeneca shot for Guillain-Barre syndrome* Rare nerve syndrome also linked some vaccinations in past* EMA assessing heart inflammation with Pfizer, Moderna shots* Studies into possible links to rare blood clots ongoing (Adds BioNTe...

Today 13:15

Canada willing to discuss COVID-19 vaccine IP waiver -statement

OTTAWA, May 7 (Reuters) - Canada on Friday said that it was ready to discuss an intellectual property rights (IP) waiver for COVID-19 vaccines while it also recognized the importance of protecting IP and the integral role industry played in devel...

Today 13:00

UPDATE 1-German panel to recommend J&J COVID vaccine for over-60s - Spiegel

(Adds RKI comment, background)BERLIN, May 7 (Reuters) - Germany's vaccine committee, known as STIKO, plans to recommend Johnson & Johnson's COVID-19 vaccine only for people over the age of 60, German magazine Der Spiegel reported on Friday, citing...

Today 12:24

Germany's STIKO to recommend J&J COVID vaccine for over-60s - Spiegel

BERLIN, May 7 (Reuters) - Germany's vaccine committee, known as STIKO, plans to recommend Johnson & Johnson's COVID-19 vaccine only for people over the age of 60, German magazine Der Spiegel reported on Friday, citing no sources.Europe's drug regu...

Today 11:58

New UK guidance on AstraZeneca will not affect rollout schedule- official

LONDON, May 7 (Reuters) - Britain's decision to advise all under 40-year-olds to take an alternative vaccine to the Oxford/AstraZeneca one will not affect the country's plan to offer a first dose to all adults by the end of July, a senior health ...

Today 11:43

UPDATE 1-Third wave of pandemic "appears to be broken" - German health minister

(Adds detail on vaccination progress, AstraZeneca decision)BERLIN, May 7 (Reuters) - The third wave of the coronavirus pandemic appears to be broken, German Health Minister Jens Spahn said on Friday, as social distancing measures and an accelerati...

Today 09:54

UPDATE 2-Germany defends AstraZeneca pivot as key to speeding vaccinations

* All adults now free to get AZ shot, on doctor's advice* Gap between doses can be as little as 4 weeks* Experts warn on reduced efficacy with shorter gap* Third wave of pandemic "appears to be broken" - minister (Recasts to lead on AstraZeneca shif...

Today 09:54

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.